Abstracts dimensional model of the instrument with group type (exercise or control) as the criterion variable to assess model invariance. RESULTS: A total of 89 participants completed the trial of which 48 were in the exercise group. Evidence of variation in the factorial structure of the EPDS between groups was found suggesting the invariance assumption may not be supported. CONCLUSIONS: The assumption that the outcome measure (EPDS) is invariant between groups within an RCT was not supported. Further investigation is required to evaluate the impact of outcome measure variance on treatment effects in clinical trials where self-report measure data is used as primary and/or secondary outcomes. To document surgical treatment patterns of uterine fibroid (UF) patients and total all-cause medical costs for UF patients in real-world practice settings using managed care claims data. METHODS: In this retrospective database study, women with a UF diagnosis between 15 and 51 years of age were selected between 2000 and 2006. An index date was defined as the date of first observed UF diagnosis. All patients were required to have continuous plan enrollment 6 months pre-and 36 months post-index date. Summary statistics for patient characteristics, probability of first UF-related surgery, any repeat UF-related surgery, and total medical and pharmacy costs (2007 US$) incurred 12 months post-index date were generated. RESULTS: A total of 109,595 patients met the study inclusion criteria. The mean age at UF diagnosis was 43 years and the mean Charlson score was 0.27. Patients with commercial insurance accounted for 91% of the population, while 75% had an HMO or PPO plan. The probability of UF-related surgery was 30.2%, 35.0%, and 38.4% within the 12-month, 24-month, and 36-month follow-up periods, respectively. Among patients with a UF-related surgery during the 36 month follow-up period, 79.6%, 7.3%, 3.3%, 13.0% had hysterectomy, myomectomy, UAE/UAO, and ablation, respectively. Mean age at first surgery (44 years) varied by surgery type with younger women more likely to undergo myomectomy. The rate of repeat surgery within one year of first surgery ranged from 1.6% (hysterectomy) to 10.5% (ablation). The mean total cost for all UF patients was $9608, 12 months post-index date. CONCLUSIONS: A substantial proportion of patients undergo UF-related surgeries within one to three years of diagnosis, with hysterectomy being the most common surgery. UF-related surgeries present significant clinical and economic implications that should be understood by private and public third party payers who bear the financial burden of UF surgical care. Patients with a diagnosis of ADHD (ICD-9-CM codes 314.00 and 314.01) comprised the study cohort and patients without an ADHD diagnosis comprised the control cohort. Study measures included demographics, hospital characteristics, admission source, discharge disposition, LOS, and costs. Generalized linear models accounting for the HCUP-NIS survey design were undertaken to adjust LOS and cost estimates. RESULTS: A total of 7,404 and 18,039 patients met the inclusion criteria for the study and control cohorts, respectively. Patients in the study cohort were 6.8 months younger than patients in the control cohort (13.8 versus 14.4 years). A higher percentage of patients in the study cohort were male (71.3% versus 45.2%) or had Medicaid (57.1% versus 48.6%) compared to the control cohort. In both cohorts, the ER was the most common admission source, approximately 90% of patients had their discharge disposition recorded as routine, and most patients were treated in urban, teaching, or large bedsize hospitals. The study cohort had longer LOS and higher costs versus the control cohort (mean [SE] . Regression analyses found the study cohort had significantly longer LOS and higher costs versus the control cohort (by 2.5 days and $1338). CONCLUSIONS: Patients hospitalized with a primary diagnosis of ODD and a secondary diagnosis of ADHD had significantly longer LOS and higher costs compared to patients with ODD but without ADHD. Clinicians and health care decision-makers should be aware of the impact ADHD has on inpatient stays among patients with ODD. The index date was defined as the dispense date of the first duloxetine prescription filled, with no duloxetine coverage in the prior 90 days. Patients were required to have at least 30 supply days of duloxetine in the 12 months post-index period. Individuals with any diagnosis of diabetic peripheral neuropathic pain or depression during the 12 months pre-index period were excluded. Five study cohorts were constructed based on the index dosage: <30 mg, 30 mg, 31-59 mg, 60 mg, and >60 mg. Patterns of duloxetine use including changes in dosage, average daily dose (ADD), adherence to duloxetine (medication possession ratio≥0.8 as high adherence) were examined across study cohorts. Regression models were performed to estimate the differences in health care costs. RESULTS: A total of 566 fibromyalgia patients were included, with 41, 163, 47, 294 and 21 in the <30 mg, 30 mg, 31-59 mg, 60 mg, and >60 mg cohorts, respectively. A total of 31.4% of patients experienced any dosage changes (increased dosage: 25.8%; decreased dosage: 15.7%). Among those who changed dosage, patients in the 31-59 mg cohort had the shortest time to change (81 days), and patients in the <30 mg cohort had the longest (149 days) time. ADD trended upward as index dose increased. Compared with patients in the 60 mg cohort, those in the <30 mg and >60 mg cohorts were less likely to be adherent (odds ratios 0.40 and 0.30, respectively, both p < 0.05). Post-index total health care costs were similar across cohorts. CONCLUSIONS: Dosage changes occurred most quickly in fibromyalgia patients with an index dose of 31-59 mg of duloxetine. Duloxetine ADD and adherence differ by index dosage, while health care costs remain similar. Thomson Reuters, Washington, DC, USA, 2 Boehringer-Ingelheim, Ridgefield, CT, USA OBJECTIVES: Hypoactive sexual desire disorder (HSDD) is characterized by persistent/ recurring deficiency of sexual fantasies or thoughts, and/or the absence of desire for sexual activity. Despite the potentially high prevalence of the condition, few studies have evaluated the cost of treating women with HSDD. The current study describes health care utilization and costs among women suffering from HSDD relative to women without evidence of female sexual dysfunction (FSD). METHODS: Women aged 18-64 with a diagnosis of HSDD (ICD-9-CM: 302.71) were identified using the Marketscan® Commercial Claims and Encounters Databases from Thomson Reuters. Women were identified between January 1, 1998-December 31, 2007 and were matched 1:3 to women without FSD (ICD-9-CM: 302.7x; 306.51) based on age, health plan type and months with medical/pharmacy benefits. Utilization and costs were evaluated during the 12, 24 and 36-month periods following HSDD diagnosis.
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Bapat B 1 , Davis K 1 , Bell KF 2 , Deal LS 2 , Talbird SE 3 1 RTI Health Solutions, Research Triangle Park, NC, USA, 2 Pfizer, Collegeville, PA, USA, 3 RTI Health Solutions, RTP, NC, USA OBJECTIVES: To document surgical treatment patterns of uterine fibroid (UF) patients and total all-cause medical costs for UF patients in real-world practice settings using managed care claims data. METHODS: In this retrospective database study, women with a UF diagnosis between 15 and 51 years of age were selected between 2000 and 2006. An index date was defined as the date of first observed UF diagnosis. All patients were required to have continuous plan enrollment 6 months pre-and 36 months post-index date. Summary statistics for patient characteristics, probability of first UF-related surgery, any repeat UF-related surgery, and total medical and pharmacy costs (2007 US$) incurred 12 months post-index date were generated. RESULTS: A total of 109,595 patients met the study inclusion criteria. The mean age at UF diagnosis was 43 years and the mean Charlson score was 0.27. Patients with commercial insurance accounted for 91% of the population, while 75% had an HMO or PPO plan. The probability of UF-related surgery was 30.2%, 35.0%, and 38.4% within the 12-month, 24-month, and 36-month follow-up periods, respectively. Among patients with a UF-related surgery during the 36 month follow-up period, 79.6%, 7.3%, 3.3%, 13.0% had hysterectomy, myomectomy, UAE/UAO, and ablation, respectively. Mean age at first surgery (44 years) varied by surgery type with younger women more likely to undergo myomectomy. The rate of repeat surgery within one year of first surgery ranged from 1.6% (hysterectomy) to 10.5% (ablation). The mean total cost for all UF patients was $9608, 12 months post-index date. CONCLUSIONS: A substantial proportion of patients undergo UF-related surgeries within one to three years of diagnosis, with hysterectomy being the most common surgery. UF-related surgeries present significant clinical and economic implications that should be understood by private and public third party payers who bear the financial burden of UF surgical care. Patients with a diagnosis of ADHD (ICD-9-CM codes 314.00 and 314.01) comprised the study cohort and patients without an ADHD diagnosis comprised the control cohort. Study measures included demographics, hospital characteristics, admission source, discharge disposition, LOS, and costs. Generalized linear models accounting for the HCUP-NIS survey design were undertaken to adjust LOS and cost estimates. RESULTS: A total of 7,404 and 18,039 patients met the inclusion criteria for the study and control cohorts, respectively. Patients in the study cohort were 6.8 months younger than patients in the control cohort (13.8 versus 14.4 years). A higher percentage of patients in the study cohort were male (71.3% versus 45.2%) or had Medicaid (57.1% versus 48.6%) compared to the control cohort. In both cohorts, the ER was the most common admission source, approximately 90% of patients had their discharge disposition recorded as routine, and most patients were treated in urban, teaching, or large bedsize hospitals. The study cohort had longer LOS and higher costs versus the control cohort (mean [SE] . Regression analyses found the study cohort had significantly longer LOS and higher costs versus the control cohort (by 2.5 days and $1338). CONCLUSIONS: Patients hospitalized with a primary diagnosis of ODD and a secondary diagnosis of ADHD had significantly longer LOS and higher costs compared to patients with ODD but without ADHD. Clinicians and health care decision-makers should be aware of the impact ADHD has on inpatient stays among patients with ODD. The index date was defined as the dispense date of the first duloxetine prescription filled, with no duloxetine coverage in the prior 90 days. Patients were required to have at least 30 supply days of duloxetine in the 12 months post-index period. Individuals with any diagnosis of diabetic peripheral neuropathic pain or depression during the 12 months pre-index period were excluded. Five study cohorts were constructed based on the index dosage: <30 mg, 30 mg, 31-59 mg, 60 mg, and >60 mg. Patterns of duloxetine use including changes in dosage, average daily dose (ADD), adherence to duloxetine (medication possession ratio≥0.8 as high adherence) were examined across study cohorts. Regression models were performed to estimate the differences in health care costs. RESULTS: A total of 566 fibromyalgia patients were included, with 41, 163, 47, 294 and 21 in the <30 mg, 30 mg, 31-59 mg, 60 mg, and >60 mg cohorts, respectively. A total of 31.4% of patients experienced any dosage changes (increased dosage: 25.8%; decreased dosage: 15.7%). Among those who changed dosage, patients in the 31-59 mg cohort had the shortest time to change (81 days), and patients in the <30 mg cohort had the longest (149 days) time. ADD trended upward as index dose increased. Compared with patients in the 60 mg cohort, those in the <30 mg and >60 mg cohorts were less likely to be adherent (odds ratios 0.40 and 0.30, respectively, both p < 0.05). Post-index total health care costs were similar across cohorts. CONCLUSIONS: Dosage changes occurred most quickly in fibromyalgia patients with an index dose of 31-59 mg of duloxetine. Duloxetine ADD and adherence differ by index dosage, while health care costs remain similar. Thomson Reuters, Washington, DC, USA, 2 Boehringer-Ingelheim, Ridgefield, CT, USA OBJECTIVES: Hypoactive sexual desire disorder (HSDD) is characterized by persistent/ recurring deficiency of sexual fantasies or thoughts, and/or the absence of desire for sexual activity. Despite the potentially high prevalence of the condition, few studies have evaluated the cost of treating women with HSDD. The current study describes health care utilization and costs among women suffering from HSDD relative to women without evidence of female sexual dysfunction (FSD). METHODS: Women aged 18-64 with a diagnosis of HSDD (ICD-9-CM: 302.71) were identified using the Marketscan® Commercial Claims and Encounters Databases from Thomson Reuters. Women were identified between January 1, 1998-December 31, 2007 and were matched 1:3 to women without FSD (ICD-9-CM: 302.7x; 306.51) based on age, health plan type and months with medical/pharmacy benefits. Utilization and costs were evaluated during the 12, 24 and 36-month periods following HSDD diagnosis.
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